Featured Research

from universities, journals, and other organizations

New Anti-cancer Drug: 200 Times More Active In Killing Tumor Cells

Date:

March 26, 2009

Source:

University of Illinois at Urbana-Champaign

Summary:

A team of researchers from the US, Europe, Taiwan and Japan has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

Share This

University of Illinois chemistry department research scientist Yonghui Zhang (left), chemist Rong Cao (center), chemistry professor Eric Oldfield and their colleagues engineered a new bisphosphonate drug that is about 200 times more effective at killing cancer cells than a bisphosphonate drug used in a recent clinical trial.

Credit: Photo by L. Brian Stauffer, U. of I. News Bureau

A team of 24 researchers from the U.S., Europe, Taiwan and Japan and led by University of Illinois scientists has engineered a new anti-cancer agent that is about 200 times more active in killing tumor cells than similar drugs used in recent clinical trials.

Related Articles

The study appears this week in the Journal of the American Chemical Society.

The new agent belongs to a class of drugs called bisphosphonates. These compounds were originally developed to treat osteoporosis and other bone diseases, but were recently found to also have potent anti-cancer and immune boosting properties.

Drug developers have tried for years to design drugs to inhibit cell survival pathways in tumor cells, focusing on a protein called Ras since nearly a third of all human cancers involve a mutation in the Ras gene that causes cell signaling to go awry. These efforts have met with limited success.

Bisphosphonates act on other enzymes, called FPPS and GGPPS, which are upstream of Ras in the cell survival pathway. Inhibiting these enzymes appears to be a more effective strategy for killing cancer cells.

When used in combination with hormone therapy in a recent clinical trial, the bisphosphonate drug zoledronate significantly reduced the recurrence of breast cancer in premenopausal women with estrogen-receptor-positive breast cancer. Similar results were reported previously for hormone-refractory prostate cancer.

But zoledronate quickly binds to bone, reducing its efficacy in other tissues.

"We're trying to develop bisphosphonates that will be very active but won't bind to the bone, because if they bind to the bone they're not going to go to breast, lung or other tissues," said University of Illinois chemistry professor Eric Oldfield, who led the new study.

Oldfield's team also wanted to design a compound that would inhibit multiple enzymes in the tumor cell survival pathway, rather than just one, an approach analogous to the use of multi-kinase inhibitors in cancer therapy.

Andrew Wang, of Academia Sinica, Taipei, and Illinois chemist Rong Cao began by producing crystallographic structures of the target enzymes and drug candidates, allowing the researchers to identify those features that would enhance the drugs' ability to bind to the enzymes. Using this and other chemical data, Illinois chemistry department research scientist Yonghui Zhang engineered new bisphosphonate compounds that bound tightly to multiple enzyme targets, but not to bone.

One of the new compounds, called BPH-715, proved to be especially potent in cell culture and effectively inhibited tumor cell growth and invasiveness.

Tadahiko Kubo, of Hiroshima University, then found that BPH-715 also killed tumor cells in mice. And Socrates Papapoulos, of Leiden University, the Netherlands, showed that the compound had a very low chemical affinity for bone.

In humans, compounds like BPH-715 and zoledronate have an added benefit in fighting cancer: They spur the proliferation of immune cells called gamma delta T-cells, which aid in killing tumor cells.

"The new drugs are about 200 times more effective than the drugs used in recent clinical trials at killing tumor cells and in activating gamma delta T-cells to kill tumor cells," Oldfield said. "They also prevent tumor progression in mice much better than do existing bisphosphonate molecules."

University of Illinois at Urbana-Champaign. "New Anti-cancer Drug: 200 Times More Active In Killing Tumor Cells." ScienceDaily. ScienceDaily, 26 March 2009. <www.sciencedaily.com/releases/2009/03/090325132458.htm>.

University of Illinois at Urbana-Champaign. (2009, March 26). New Anti-cancer Drug: 200 Times More Active In Killing Tumor Cells. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2009/03/090325132458.htm

University of Illinois at Urbana-Champaign. "New Anti-cancer Drug: 200 Times More Active In Killing Tumor Cells." ScienceDaily. www.sciencedaily.com/releases/2009/03/090325132458.htm (accessed March 3, 2015).

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 3, 2015 — Limp or firm, your handshake conveys subliminal social cues. Now, research reveals it also transmits chemical signals that could explain why the greeting evolved in the first ... full story

Mar. 3, 2015 — Loneliness brought about by the death of a spouse can trigger a wider network of depression-like symptoms, a study has found, but authors suggest that doctors are often too quick to attribute these ... full story

Mar. 3, 2015 — Family Based Interpersonal Psychotherapy (FB-IPT) is more effective in treating preadolescent children with depression compared to child-centered therapy (CCT), a recent study has found. ... full story

Mar. 3, 2015 — Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to new research. The scientists conducted a comprehensive survey of ... full story

Mar. 3, 2015 — Scientists have succeeded in producing cartilage formed from embryonic stem cells that could in future be used to treat the painful joint condition osteoarthritis. With their huge capacity to ... full story

Mar. 3, 2015 — Everyone worries about losing their memory as they grow older—memory loss remains one of the most common complaints of the elderly. But the molecular reasons behind the processes remain unclear, ... full story

Mar. 3, 2015 — A strong link has been made between subthreshold manic episodes and likelihood of developing bipolar disorder in children of parents with bipolar disorder. The study’s findings could improve ... full story

Mar. 2, 2015 — Despite sharp increases in spending on cancer treatment, cancer mortality rates in the United States have decreased only modestly since 1970, a study has found. "Our results suggest that cancer care ... full story

Mar. 2, 2015 — In the first study of its kind since the 1920s, rats in New York City were found to carry a flea species capable of transmitting plague pathogens. Among them: 500-plus Oriental rat fleas, notorious ... full story

Mar. 2, 2015 — A newly published study is the first to report an association between bisphenol-A (BPA), a common plasticizer used in a variety of consumer food and beverage containers, with autism spectrum disorder ... full story

Featured Videos

Mom Triumphs Over Tragedy, Helps Other Families

AP (Mar. 3, 2015) — After her son, Dax, died from a rare form of leukemia, Julie Locke decided to give back to the doctors at St. Jude Children&apos;s Research Hospital who tried to save his life. She raised $1.6M to help other patients and their families. (March 3)
Video provided by AP

Woman Convicted of Poisoning Son

AP (Mar. 3, 2015) — A woman who blogged for years about her son&apos;s constant health woes was convicted Monday of poisoning him to death by force-feeding heavy concentrations of sodium through his stomach tube. (March 3)
Video provided by AP

Jan. 22, 2013 — In lab tests, juice from rice cells knocked out two kinds of human cancer cells as well or better than the potent anti-cancer drug Taxol. Plus, it did something extra: it left normal cells ... full story

Jan. 3, 2013 — Researchers in Japan report today that they have succeeded for the first time in creating cancer-specific immune system cells called killer T lymphocytes from induced pluripotent stem cells (iPS ... full story

Mar. 7, 2011 — Researchers have attempted to capitalize upon natural immune responses against tumors to develop new therapies by generating dendritic cells (DCs) to use as vaccines to augment the T-cell responses ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.